GettingToMarketBiotechPharma.pptVIP

The 16th AnnualThe Nuts and Bolts of Business PlansMIT Course 15.975January 2005 * Getting To Market: Biotech/Pharma Tuesday November 23, 2004, 7-9 PM Room 56-114 PANEL DISCUSSION On the Panel: Duncan A. Greenhalgh, PhD: Testa Hurwitz Thibeault LLP Amir Nashat, PhD: Polaris Venture Partners Robert H. Rubin,MD PhD: Assoc Dtr, Div of Infectious Diseases- Brigham Women’s Hospital Anthony J. Sinskey, ScD: MIT Professor of Microbiology Founder of Metabolix William F. Swiggart, JD: Swiggart Agin Moderator : Joe Hadzima, Senior Lecturer MIT Sloan School Main Street Partners LLC PANELIST: Duncan Greenhalgh, Testa, Hurwitz Thibeault LLP Duncan A. Greenhalgh, Ph.D. is an associate in the Patent and Intellectual Property Practice Group. He specializes in the protection and enforcement of intellectual property rights primarily in the field of life sciences, and represents private and publicly traded companies, and medical and academic institutions. Dr. Greenhalgh received his B.Sc., with honors, in Biotechnology, from the University of Leeds, U.K., his Ph.D. in Biochemistry from the University of Leeds, U.K., and his J.D., magna cum laude, from Suffolk University law school. He worked for four years as a postdoctoral research associate in the Department of Chemistry at Massachusetts Institute of Technology under Nobel Laureate Har Gobind Khorana. Getting To Market: Biotech/Pharma PANELIST: Steven H. Holtzman, Founder, Chairman, President and CEO of Infinity Pharmaceuticals, Inc. From early 1994 through mid-2001, Mr. Holtzman served as the Chief Business Officer of Millennium Pharmaceuticals, Inc. Prior to joining Millennium, from 1986 to 1994, Mr. Holtzman was a founder and the first employee of DNX Corporation, the first commercial enterprise devoted to the development of biomedical and pharmaceutical applications of transgenic animal technology. From 1996 to 2001, Steven was appointed by President Clinton as the sole individual from the pharmaceutical or biot